Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
NCT ID: NCT04408820
Last Updated: 2025-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2104 participants
OBSERVATIONAL
2020-06-01
2025-06-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
NCT01750190
Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
NCT04059913
Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia
NCT01244763
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
NCT01147666
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
NCT02174627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who are eligible for the survey will be registered within 14 days after the start of treatment with roxadustat (including the start day of treatment). For all registered patients (including discontinuations/dropouts), the investigator will enter the necessary information in the case report form (CRF) and send it immediately after the end of the specified observation period for each patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Roxadustat
Participants will receive oral dose of roxadustat.
Roxadustat
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Roxadustat
Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Astellas Pharma Inc.
Role: STUDY_DIRECTOR
Astellas Pharma Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site JP00023
Aichi, , Japan
Site JP00005
Akita, , Japan
Site JP00002
Aomori, , Japan
Site JP00012
Chiba, , Japan
Site JP00038
Ehime, , Japan
Site JP00018
Fukui, , Japan
Site JP00040
Fukuoka, , Japan
Site JP00007
Fukushima, , Japan
Site JP00021
Gifu, , Japan
Site JP00010
Gunma, , Japan
Site JP00034
Hiroshima, , Japan
Site JP00001
Hokkaido, , Japan
Site JP00028
Hyōgo, , Japan
Site JP00008
Ibaraki, , Japan
Site JP00017
Ishikawa, , Japan
Site JP00037
Kagawa, , Japan
Site JP00046
Kagoshima, , Japan
Site JP00014
Kanagawa, , Japan
Site JP00039
Kochi, , Japan
Site JP00043
Kumamoto, , Japan
Site JP00026
Kyoto, , Japan
Site JP00024
Mie, , Japan
Site JP00004
Miyagi, , Japan
Site JP00045
Miyazaki, , Japan
Site JP00020
Nagano, , Japan
Site JP00042
Nagasaki, , Japan
Site JP00029
Nara, , Japan
Site JP00015
Niigata, , Japan
Site JP00003
Numakunai, , Japan
Site JP00033
Okayama, , Japan
Site JP00047
Okinawa, , Japan
Site JP00027
Osaka, , Japan
Site JP00044
Ōita, , Japan
Site JP00041
Saga, , Japan
Site JP00011
Saitama, , Japan
Site JP00025
Shiga, , Japan
Site JP00032
Shimane, , Japan
Site JP00022
Shizuoka, , Japan
Site JP00009
Tochigi, , Japan
Site JP00036
Tokushima, , Japan
Site JP00013
Tokyo, , Japan
Site JP00031
Tottori, , Japan
Site JP00016
Toyama, , Japan
Site JP00030
Wakayama, , Japan
Site JP00006
Yamagata, , Japan
Site JP00035
Yamaguchi, , Japan
Site JP00019
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsuruya K, Sugamori H, Tanaka Y, Wakasugi N, Ito Y. Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan. Expert Opin Pharmacother. 2025 Mar;26(4):503-517. doi: 10.1080/14656566.2025.2462181. Epub 2025 Feb 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1517-MA-3318
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.